MAPT and Alzheimer disease: ADNI is a longitudinal, multi-center observational program (2004–present) designed to validate imaging and fluid biomarkers for AD trials, with serial 3D MRI and PET (amyloid, tau, FDG), CSF, genetics, and standardized clinical assessments at roughly 6–12-month intervals.